Loading...
•
Sep 30, 2024
Innoviva Q3 2024 Earnings Report
Reported strong revenue growth driven by GSK royalty assets and IST commercial products.
Key Takeaways
Innoviva reported strong Q3 2024 financial results, driven by solid performance from core GSK royalty assets and accelerating sales from IST commercial products. The company is on track to submit an NDA for zoliflodacin to the U.S. FDA in early 2025.
Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth.
Innoviva Specialty Therapeutics’ (IST) marketed portfolio achieved U.S. net product sales of $19.7 million, reflecting 68% year-over-year growth
XACDURO® was nominated for the Best Biotechnology Product by The Galien Foundation USA
Company is on track to submit a New Drug Application (“NDA”) for zoliflodacin to the U.S. FDA in early 2025.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Company remains focused on prudent capital allocation in quest to maximize shareholder value and see multiple opportunities for continued value creation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...